Immunogen Given Consensus Recommendation of “Hold” by Analysts (NASDAQ:IMGN)
Immunogen (NASDAQ:IMGN) has earned an average rating of “Hold” from the twelve brokerages that are presently covering the stock, Analyst Ratings Network reports. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and seven have given a buy rating to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $17.58.
Shares of Immunogen (NASDAQ:IMGN) traded up 0.22% during mid-day trading on Tuesday, hitting $13.66. 269,391 shares of the company’s stock traded hands. Immunogen has a one year low of $12.55 and a one year high of $20.25. The stock’s 50-day moving average is $15.88 and its 200-day moving average is $15.58. The company’s market cap is $1.170 billion.
Immunogen (NASDAQ:IMGN) last announced its earnings results on Friday, January 31st. The company reported ($0.29) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.18) by $0.11. The company had revenue of $30.10 million for the quarter, compared to the consensus estimate of $18.16 million. During the same quarter last year, the company posted ($0.29) earnings per share. Immunogen’s revenue was up 1057.7% compared to the same quarter last year. On average, analysts predict that Immunogen will post $-0.67 earnings per share for the current fiscal year.
Several analysts have recently commented on the stock. Analysts at Zacks upgraded shares of Immunogen from a “neutral” rating to an “outperform” rating in a research note on Monday. They now have a $15.90 price target on the stock. Separately, analysts at Guggenheim raised their price target on shares of Immunogen from $14.00 to $15.00 in a research note on Friday, January 31st.
ImmunoGen, Inc (NASDAQ:IMGN) develops targeted, antibody-based therapeutics for the treatment of cancer.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.